PTO/SB/01 (10-00) Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number 421/29/2 **DECLARATION FOR UTILITY OR** First Named Inventor Nadia Malouf **DESIGN** PATENT APPLICATION **COMPLETE IF KNOWN** (37 CFR 1.63) **Application Number** Filing Date ▼ Declaration ☐ Declaration Submitted after Initial OR Submitted Group Art Unit Filing (surcharge (37 CFR 1.16 (e)) with Initial Filing **Examiner Name** required)

As a below named inventor, I hereby declare that:							
My residence, mailing address, and citizenship are as stated below next to my name.							
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:							
PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME							
(Title of the Invention)							
☐ is attached hereto							
OR as United States Application Number or PCT International was filed on (MM/DD/YYYY)							
Application Number and was amended on (MM/DD/YYYY) (if applicable).							
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.							
I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.							
I hereby claim foreign priority benefits under 35 U S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.							
Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES NO			
☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:							
I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.							
Application Number(s)	Filing Dat	te (MM/DD/YYYY)	Additional provisional land				
60/258,169	12/22/	12/22/2000		Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.			

[Page 1 of 2]
Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: Customer Number or Bar Code Label OR Correspondence address below								
Name PATENT TRADEMARK OFFICE								
Address								
Address								
City				State		ZIP		
Country	Telephone					Fax	Fax	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.								
NAME OF SOLE OR FIRST IN	/ENTOR:] A peti	tion has been file	ed for this uns	signed inventor	
Given Name (first and middle [if any]) Nadia					Family Name or Surname Malouf			
Inventor's Signature						Date		
Residence: City Durham			State	NC	Country USA	Citizenship	USA	
Mailing Address 13 Surrey Lane								
Mailing Address	L							
City Durham	State	NC		ZIP	27707	Country	USA	
NAME OF SECOND INVENTOR	:			A petit	tion has been file	ed for this uns	igned inventor	
Given Name (first and middle [if any]) Timothy C.				Family Name or Surname Nichols				
Inventor's Signature Date								
Residence: City Chapel Hill			State	NC	Country USA		TICA	
Mailing Address 322 Ferguson Road								
Mailing Address								
7				27514	Country	USA		
Additional inventors are being named on thesupplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.								



Atty Docket: 421/29

ASSIGNMENT

WHEREAS, we, Nadia Malouf, City of Durham, State of North Carolina, and Timothy C. Nichols, City of Chapel Hill, State of North Carolina (hereinafter "Assignors"), have invented certain new and useful improvements in PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME for which an application for Letters Patent of the United States was made on December 22, 2000 as U.S. Provisional Patent Application Serial No. 60/258,169.

AND, WHEREAS, The University of North Carolina, a non-profit organization located at Chapel Hill, North Carolina (hereinafter "Assignee"), is desirous of acquiring an interest therein.

NOW, THEREFORE, To Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors have sold and by these presents do hereby sell, assign, transfer and convey unto the said Assignee, its successors and assigns, his/her or their entire right, title and interest in and to said invention and application, and in and to any and all United States patent applications filed pursuant to 35 U.S.C. § 111(a) pertaining to said invention and/or which claim priority to the United States provisional patent application referenced above, and in and to any and all continuations, continuations-in-part, or divisions of any U.S. or foreign patent application filed on the invention, and in and to any and all Letters Patent of the United States of America and all foreign countries or reissues or extensions thereof which may be granted therefor or thereon, for the full end of the term for which said Letters Patent may be granted, together with his/her or their right to claim the priority of said application in all foreign countries in accordance with the International Convention, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignors if this assignment and sale had not been made.

Assignors hereby request that said Letters Patent be issued in accordance with this assignment.

Assignors further covenant and agree that, at the time of the execution and delivery of these presents, Assignors possess full title to the invention and application abovementioned, and that they have the unencumbered right and authority to make this assignment.

Assignors further covenant and agree, and likewise bind their heirs, legal representatives and assigns, to promptly communicate to said Assignee or its representatives any facts known to them relating to said invention, to testify in any interference or legal proceedings involving said invention, to execute any additional papers which may be requested to confirm the right of the Assignee, its representatives, successors and assigns to secure patent or similar protection for the said invention in all countries and to vest in the Assignee complete title to the said invention and Letters Patent, without further compensation, but at the expense of said Assignee, its successors, assigns and other legal representatives.

Executed this 21	day of Morch 2001.
Witnessed by:	Nadia Mah A
Name Stew R Worden	3/21/01 Date
Name	Date
<i>,</i>	* * * * * * * * * *
Executed this2/da	ay of <u>March</u> 2001.
	Timothy C. Nichols
Witnessed by:	
Name Commission EXP 5/12/	3/21/01 ogate
Name	Date

Date of Deposit being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents, Washington, D.C.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malouf et al.

Group Art Unit: Not Assigned

Serial No.: Not Assigned

Examiner: Not Assigned

Filed: Herewith

Docket No.: 421/29/2

Confirmation No.: Not Assigned

PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS

USING SAME

STATEMENT THAT SEQUENCE LISTING AND COMPUTER READABLE COPY ARE THE SAME

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821(f), applicants hereby state that the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing on paper.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 12-20-0

By:

Arles A. Taylor, Jr.

Registration No. 39,395

Suite 1400 University Tower 3100 Tower Boulevard Durham, North Carolina 27707 Telephone: (919) 493-8000 Facsimile: (919) 419-0383

Customer No. Bar Code Label:

421/29/2

AAT/ajm

25297